Not finding it? Sign in to also search OpenAlex live.
-
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
Larry Don Anderson, Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, +21 more
3citations -
Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer: A subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.2024 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Maggie Banys‐Paluchowski, Timo Basali, Steffi Hartmann, Jana de Boniface, Oreste Gentilini, Elmar Stickeler, +13 more
0citations -
Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dl on anti-C5 therapy: Subgroup analysis of the appulse-pnh Phase 3b trial2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Austin Gladston Kulasekararaj, Flore Sicre de Fontbrune, Anna Gayà, Ilene Ceil Weitz, David J. Kuter, David J. Araten, +15 more
0citations -
POS0676 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS AGED ≥75 YEARS: A POST HOC SUBGROUP ANALYSIS OF THE FINCH 4 LONG-TERM EXTENSION (LTE) STUDY2022 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access
Daniel Aletaha, R. Westhovens, B. Combe, Jacques‐Eric Gottenberg, M. H. Buch, R. Caporali, +7 more
3citations -
THU0204 A SUBGROUP ANALYSIS OF LOW DISEASE ACTIVITY AND REMISSION FROM PHASE 3 STUDY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARDS2020 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access
J.E. Gottenberg, MH Buch, Roberto Felice Caporali, Grace C. Wright, Tsutomu Takeuchi, KENNETH C. KALUNIAN, +6 more
2citations -
MPN-161: Benefit of Rusfertide Maintained in Patients With Low-Risk or High-Risk Polycythemia Vera: Efficacy and Safety Subgroup Analysis From the Randomized Controlled Phase 3 VERIFY Study2026 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment
Naveen Pemmaraju, Valentín García‐Gutiérrez, Aniket Bankar, Kristen Marie Pettit, Joseph Shatzel, Alessandro Lucchesi, +19 more
0citations -
Abstract PO3-23-03: Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial2024 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Maggie Banys‐Paluchowski, Steffi Hartmann, Jana de Boniface, Oreste Gentilini, Timo Basali, Elmar Stickeler, +23 more
0citations -
Abstract PO1-23-02: Magnetic seeds used for the detection of target lymph nodes after neoadjuvant therapy for early breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial2024 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Hans‐Christian Kolberg, Steffi Hartmann, Maggie Banys‐Paluchowski, Elmar Stickeler, Jana de Boniface, Oreste Gentilini, +9 more
0citations -
Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.2020 Journal of Clinical Oncology conference-abstract Medicine Multiple Myeloma Research and Treatments
Cyrille Touzeau, Philippe Moreau, Aurore Perrot, Cyrille Hulin, Mamoun Dib, Mourad Tiab, +13 more
8citations -
Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study2020 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Kenshi Suzuki, Ashutosh D. Wechalekar, Kihyun Kım, Chihiro Shimazaki, Jin Seok Kim, Takayuki Ikezoe, +15 more
2citations -
MM-350: Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN2020 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Multiple Myeloma Research and Treatments
Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej J. Jakubowiak, Leyla Osman Shune, Ashraf Z. Badros, +8 more
3citations -
Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter2021 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, Nicole Straetmans, +5 more
1citations -
POS1115 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SUBGROUP ANALYSES BY BASELINE SYNDESMOPHYTES AND C-REACTIVE PROTEIN STATUS
Xenofon Baraliakos, Désirée M F M van der Heijde, Pedro Machado, Victoria Navarro‐Compán, Lianne S. Gensler, P. Pertel, +4 more
3citations -
FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)2020 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
Philip Helliwell, Filip E Van den Bosch, Laura C. Coates, Dafna D. Gladman, Chantal T. Tasset, Luc Meuleners, +6 more
4citations -
MM-329 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)2024 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Multiple Myeloma Research and Treatments
Meletios Athanasios Dimopoulos, Pieter Sonneveld, Paula Rodríguez‐Otero, Hang Quach, P. Joy Ho, Meral Beksaç, +33 more
3citations -
THU0188 EFFICACY OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH POOR PROGNOSTIC FACTORS: POST HOC ANALYSIS OF FINCH 32020 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies
Daniel Aletaha, René Westhovens, Cécile Gaujoux-Viala, Giovanni Adami, A K Matsumoto, Paul Bird, +6 more
0citations -
Abstract P5-14-01: Transcriptomic insights into lobular breast cancer biology: a retrospective analysis of the MINDACT clinical trial2023 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Christine Desmedt, Ha-Linh Nguyen, Sabine C. Linn, Otto Metzger, Coralie Poncet, Jelle Wesseling, +15 more
0citations -
Abstract 1727: CD8+ T cells in the invasive margin combined with FOXP3+ T cells in the tumor center significantly associate with survival in resectable gastric cancer, a post-hoc analysis of the Dutch D1/D2 trial
Tanya T.D. Soeratram, Hedde D. Biesma, Jacqueline Egthuijsen, Elma Meershoek‐Klein Kranenbarg, Henk H. Hartgrink, Cornelis JH van de Velde, +5 more
0citations -
OP0323 HAND-DOMINANT JOINT INVOLVEMENT PATTERN ASSOCIATES WITH FAVORABLE, AND POLYARTHRITIS WITH UNFAVORABLE, TREATMENT RESPONSE TO BOTH csDMARDs AND bDAMRDs IN EARLY RHEUMATOID ARTHRITIS: A COMBINED ANALYSIS OF NORD-STAR AND BeSt TRIALS2025 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access
Yasuo Nagafuchi, Tjardo Daniël Maarseveen, Kristina Lend, Arvid Dahlstrand Rudin, B. Gudbjornsson, D. Nordström, +15 more
0citations -
The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial
Régis Peffault de Latour, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yutaka Ueda, Carlos de Castro, Samopriyo Maitra, +3 more
1citations